Filing Flows › Palisade Bio (PALI) › Stock forecast & fair value
Palisade Bio (PALI) stock forecast and price target
Palisade Bio (PALI) trades at $1.13. 10 analysts' median price target is $7.50 (+564%), from $5.00 to $25.00.
Palisade Bio's latest quarter
Palisade Bio, Q2 2026: revenue $500K, net loss $10.6M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PALI stock?
The median of 10 analysts' 12-month targets is $7.50, +564% from $1.13; the range is $5.00 to $25.00. The average rating is strong buy.
Does Palisade Bio usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is PALI stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.